Ernst Geutjes

Ernst Geutjes is a biotechnology entrepreneur and investment professional with deep expertise in cancer research, oncology drug development and venture creation. He has worked on both sides of the table as an executive in new venture creation and as an investor in oncology start-ups. Since 2014, he has been with Aglaia Oncology Funds, a boutique venture capital firm that is specialized in early-stage oncology therapeutics investments and venture creation, initially as a partner and currently as venture partner. He was the interim managing director of Sapreme Technologies and board observer of Inthera Bioscience and Macrophage Pharma.
‍

Before Aglaia he worked as business development manager for TNO where he was involved in spinning-out technology originating from TNO. He lead the idea to business concept for Dutch DNA biotech leading to its spin-out. Dutch DNA was acquired by Gingo Bioworks in 2021. He developed this entrepreneurial spirit in his academic life working in the laboratory of Hidde Ploegh at Harvard Medical School and at the translational cancer research group of Prof. Rene Bernard at the Netherlands Cancer Institute.